IPC registers 4 lakh ADRs since 2010 towards strengthening India specific drug safety database
The Ghaziabad-based Indian Pharmacopoeia Commission (IPC), the nodal coordinating centre (NCC) for Pharmacovigilance Programme of India (PvPI), has generated 4 lakh adverse drug reactions since 2010 towards strengthening India specific drug safety database.
This according to IPC officials will help in effective data mining and proper signal detection.
IPC has also chalked out its plan to increase the number of ADR monitoring centres (AMCs) from the current 270 AMCs to 300 AMCs by the end of the financial year in March 2020.
The Central Drugs Standard Control Organization (CDSCO) under the Union health ministry had initiated a nation-wide PvPI in July 2010. This got further expanded and for administrative reasons was shifted to Ghaziabad-based IPC.
Taking the PvPI one notch higher, the CDSCO is also planning to strengthen pharmacovigilance systems for vaccine ADR in collaboration with global regulators, PvPI and immunization programme of India to meet the requirements for reporting vaccine ADRs.
This will be instrumental in achieving vaccine pharmacovigilance right from collecting to coding and finally sending individual case safety reports (ICSRs) to PvPI.
IPC Ghaziabad has also formally started functioning as WHO collaborative centre for PV since 2017 to support World Health Organization (WHO) member countries in establishing pharmacovigilance programme (PV).
IPC-PV division has been assigned the status of WHO collaborating centre which will help promote medicine safety not only in India and globally but will also provide guidelines and support in policy decision making process of WHO.
IPC has also been assigned to update information on ADRs that is being reported in India from across all its centres through Vigiflow software to the Uppsala Monitoring Centre (UMC) in Sweden, which is WHO’s collaborating centre for international drug monitoring.
This will help PvPI to share WHO responsibility on expanding the scope of PV for the global population and effective integration of PV with national health programmes globally and in India.
Source : pharmabiz